Latest Labstyle (DRIO) Headlines
LabStyle Innovations, Creator of Dario(TM) Diabetes mHealth Solution, to present at the 26th Annual Roth Conference on March 11, 2014
PR Newswire - Thu Mar 06, 3:01PM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes mHealth Solution, today announced that its president and chief executive officer, Mr. Erez Rafael, will be presenting at the 26th Annual Roth Conference. The presentation is scheduled for Tuesday, March 11, 2014 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) at the Ritz Carlton, Laguna Niguel, California.
LabStyle Innovations Announces 2013 Year End Results and Highlights Key Achievements and Anticipated 2014 Milestones
PR Newswire - Wed Mar 05, 6:15AM CST
LabStyle Innovations Corp. (OTCQB/OTCBB: DRIO), developer of the Dario(TM) Diabetes Management Solution, reported today its financial and operational results for the year ended December 31, 2013. The company also presented an overview of recent corporate achievements and anticipated milestones for 2014.
LabStyle Innovations Closes Private Placement Financing
PR Newswire - Thu Feb 20, 6:15AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, announced today that it has successfully closed its previously announced $4.19 million common stock and warrant private placement financing that priced on February 13, 2014.
LabStyle Innovations Announces Pricing of $4.19 Million Private Placement Financing
PR Newswire - Thu Feb 13, 8:52AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Platform today announced that it has entered into a definitive securities purchase agreement with institutional and accredited investors to raise gross proceeds of $4.19 million at a price of $1.88 per unit in a private placement transaction. Each unit consists of one common share (for an aggregate of 2,226,956 shares to be sold) and three quarters (0.75) of one common share purchase warrant (for an aggregate of 1,670,216 warrants to be sold). The units will immediately detach and will not be separate securities. Each whole warrant entitles the holder to acquire one common share at a price of $2.35 for a period of five years from closing and contain certain anti-dilution provisions.
LabStyle Innovation Signs Agreement with uHealth to Exclusively Distribute the Dario(TM) Blood Glucose Monitoring Device in Australia
PR Newswire - Tue Feb 04, 6:00AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of the Dario(TM) Diabetes Management Platform, announced today that the company has signed an agreement with uHealth Australia Pty Limited (uHealth), a leading distributor of digital health and surgical innovations, to exclusively distribute in Australia the Dario(TM) blood glucose monitoring device, one of the three main components of the Dario(TM) platform.
LabStyle President and CEO Erez Raphael to Present and Demonstrate Dario(TM) at the Biotech Showcase 2014 in San Francisco, January 13, 2014 at 8:30 a.m.
Business Wire - Wed Jan 08, 5:59AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that company president and chief executive officer Mr. Erez Raphael will present at the Biotech Showcase 2014 on Monday, January 13, 2014 at 8:30 a.m., 55 Cyril Magnin Street, San Francisco, Level 4, Cyril Magnin Foyer. Mr. Raphael will address participants on the topic: "LabStyle Innovations Corp. (OTCQB RIO) End-to-End Smart Solutions for Diabetes in a Mobile Age." He will also give a hands-on demonstration of the Dario(TM) software and related blood glucose monitoring system and be available to answer questions.
LabStyle Innovations Files 510(k) in the U.S. for FDA Clearance of the Dario(TM) Blood Glucose Monitoring System
PR Newswire - Tue Jan 07, 6:00AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that it has filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario(TM) Blood Glucose Monitoring System.
Diabetes Advocate and Opinion Leader David Edelman Joins LabStyle Innovations as Product Strategy Director
PR Newswire - Wed Dec 18, 6:00AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced that diabetes advocate and opinion leader David Edelman has joined the company as the new director of product strategy. He is also the newest member of the company's scientific advisory board (SAB).
LabStyle Innovations Commences World Roll-Out of the Dario(TM) Diabetes Management Platform with Market Launch of iOS App in the United Kingdom, New Zealand and Australia
PR Newswire - Thu Dec 12, 6:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes and related blood glucose monitoring, announced that the world roll-out of the Dario(TM) diabetes management platform is now in progress with today's market launch of the Dario(TM) iOS app in the United Kingdom, New Zealand and Australia.
LabStyle Innovations Appoints Mr. Gadi Levin as Chief Financial Officer
PR Newswire - Wed Nov 27, 11:00AM CST
LabStyle Innovations Corp. (OTCQB RIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes management and related blood glucose monitoring, announced that Mr. Gadi Levin, CPA, MBA, has been appointed as the company's chief financial officer, secretary and treasurer.
LabStyle Innovations Signs InnoMed to Exclusively Distribute the Dario(TM) Diabetes Management Platform's Blood Glucose Monitoring Device in New Zealand
PR Newswire Europe - Tue Nov 19, 8:28AM CST
RAMAT GAN, Israel, November 19, 2013 /PRNewswire/ --
LabStyle Innovations Welcomes Dennis M. McGrath to its Board of Directors
PR Newswire - Thu Nov 14, 6:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes and related blood glucose monitoring, announced today that medical device industry expert Dennis M. McGrath has joined the company's Board of Directors.
LabStyle Innovations Reports Third Quarter 2013 Results And Provides Business Update
PR Newswire - Tue Nov 12, 7:19AM CST
LabStyle Innovations Corp. (OTCQB/OTCBB: DRIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes management and related blood glucose monitoring, reported today its financial and operational results for the three and nine months ending on September 30, 2013. The company also provided a business update and its plans for the coming months.
LabStyle Innovations Announces that the European Market Launch of the Dario(TM) Diabetes Management Platform iOS Mobile App Will Begin on December 12, 2013
PR Newswire - Mon Nov 04, 6:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes and related blood glucose monitoring, announced today the official European launch date for the Dario(TM) iOS mobile application.
LabStyle Innovations Executive Chairman's Presentation at Cleveland Clinic's 2013 Medical Innovation Summit Now Available Online
Business Wire - Mon Oct 21, 9:10AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of a diabetes-related, cloud-based mobile health (mHealth) platform and the Dario(TM) blood glucose monitoring system for patients and caregivers, announces that a presentation delivered by Executive Chairman Dr. Oren Fuerst at Cleveland Clinic's 2013 Medical Innovation Summit highlighting LabStyle's latest developments is now available at www.mydario.com and at http://www.slideshare.net/oren68/dario-invest...veland-adb.
Dario Smartphone-Based Diabetes Management System Featured in Diabetes Daily Blog
Business Wire - Wed Sep 18, 3:31PM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) smartphone-based medical device and diabetes management system, announces that Dario is the subject of a comprehensive profile in Diabetes Daily, a leading online support network for people with diabetes. The article is available at:
LabStyle Innovations to Present at the Rodman & Renshaw 15TH Annual Healthcare Conference
Business Wire - Wed Sep 04, 7:00AM CDT
LabStyle Innovations Corp. (OTCQB RIO), developer of the Dario(TM) smartphone-based medical device and diabetes management system, announces its participation in the Rodman & Renshaw 15th Annual Healthcare Conference, to be held September 9-10, 2013 at the Millennium Broadway Hotel in New York City.
LabStyle Innovations Names Shoshana Friedman Vice President of Clinical and Regulatory Affairs
Business Wire - Tue Sep 03, 7:00AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), the developer of the Dario(TM) smartphone-based glucose monitor and diabetes data-management system, today announced that Shoshana (Shosh) Friedman has joined the company as Vice President Clinical and Regulatory Affairs, with responsibility for all clinical studies and worldwide regulatory affairs for Dario.
LabStyle Innovations Reports Second Quarter Results and Provides Business Update
Business Wire - Wed Aug 14, 5:38PM CDT
LabStyle Innovations Corp. (OTCQB/OTCBB RIO), developer of the Dario(TM) smartphone-based medical device and diabetes management system, today reported its financial and operational results for the three and six months ended June 30, 2013 and provided a business update.
LabStyle Innovations, Creator of Dario(TM) Diabetes mHealth Solution, to present at the 26th Annual Roth Conference on March 11, 2014
PR Newswire - Thu Mar 06, 3:01PM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes mHealth Solution, today announced that its president and chief executive officer, Mr. Erez Rafael, will be presenting at the 26th Annual Roth Conference. The presentation is scheduled for Tuesday, March 11, 2014 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) at the Ritz Carlton, Laguna Niguel, California.
LabStyle Innovations Announces 2013 Year End Results and Highlights Key Achievements and Anticipated 2014 Milestones
PR Newswire - Wed Mar 05, 6:15AM CST
LabStyle Innovations Corp. (OTCQB/OTCBB: DRIO), developer of the Dario(TM) Diabetes Management Solution, reported today its financial and operational results for the year ended December 31, 2013. The company also presented an overview of recent corporate achievements and anticipated milestones for 2014.
LabStyle Innovations Closes Private Placement Financing
PR Newswire - Thu Feb 20, 6:15AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) Diabetes Management Solution, announced today that it has successfully closed its previously announced $4.19 million common stock and warrant private placement financing that priced on February 13, 2014.
LabStyle Innovations Announces Pricing of $4.19 Million Private Placement Financing
PR Newswire - Thu Feb 13, 8:52AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Platform today announced that it has entered into a definitive securities purchase agreement with institutional and accredited investors to raise gross proceeds of $4.19 million at a price of $1.88 per unit in a private placement transaction. Each unit consists of one common share (for an aggregate of 2,226,956 shares to be sold) and three quarters (0.75) of one common share purchase warrant (for an aggregate of 1,670,216 warrants to be sold). The units will immediately detach and will not be separate securities. Each whole warrant entitles the holder to acquire one common share at a price of $2.35 for a period of five years from closing and contain certain anti-dilution provisions. LabStyle Innovation Signs Agreement with uHealth to Exclusively Distribute the Dario(TM) Blood Glucose Monitoring Device in Australia
PR Newswire - Tue Feb 04, 6:00AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) Diabetes Management Platform, announced today that the company has signed an agreement with uHealth Australia Pty Limited (uHealth), a leading distributor of digital health and surgical innovations, to exclusively distribute in Australia the Dario(TM) blood glucose monitoring device, one of the three main components of the Dario(TM) platform. LabStyle President and CEO Erez Raphael to Present and Demonstrate Dario(TM) at the Biotech Showcase 2014 in San Francisco, January 13, 2014 at 8:30 a.m.
Business Wire - Wed Jan 08, 5:59AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that company president and chief executive officer Mr. Erez Raphael will present at the Biotech Showcase 2014 on Monday, January 13, 2014 at 8:30 a.m., 55 Cyril Magnin Street, San Francisco, Level 4, Cyril Magnin Foyer. Mr. Raphael will address participants on the topic: "LabStyle Innovations Corp. (OTCQB RIO) End-to-End Smart Solutions for Diabetes in a Mobile Age." He will also give a hands-on demonstration of the Dario(TM) software and related blood glucose monitoring system and be available to answer questions. LabStyle Innovations Files 510(k) in the U.S. for FDA Clearance of the Dario(TM) Blood Glucose Monitoring System
PR Newswire - Tue Jan 07, 6:00AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced today that it has filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario(TM) Blood Glucose Monitoring System. Diabetes Advocate and Opinion Leader David Edelman Joins LabStyle Innovations as Product Strategy Director
PR Newswire - Wed Dec 18, 6:00AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of Dario(TM), a cloud-based, mobile health platform for diabetes and blood glucose monitoring, announced that diabetes advocate and opinion leader David Edelman has joined the company as the new director of product strategy. He is also the newest member of the company's scientific advisory board (SAB). LabStyle Innovations Commences World Roll-Out of the Dario(TM) Diabetes Management Platform with Market Launch of iOS App in the United Kingdom, New Zealand and Australia
PR Newswire - Thu Dec 12, 6:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes and related blood glucose monitoring, announced that the world roll-out of the Dario(TM) diabetes management platform is now in progress with today's market launch of the Dario(TM) iOS app in the United Kingdom, New Zealand and Australia.
LabStyle Innovations Appoints Mr. Gadi Levin as Chief Financial Officer
PR Newswire - Wed Nov 27, 11:00AM CST
LabStyle Innovations Corp. (OTCQB
RIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes management and related blood glucose monitoring, announced that Mr. Gadi Levin, CPA, MBA, has been appointed as the company's chief financial officer, secretary and treasurer. LabStyle Innovations Signs InnoMed to Exclusively Distribute the Dario(TM) Diabetes Management Platform's Blood Glucose Monitoring Device in New Zealand
PR Newswire Europe - Tue Nov 19, 8:28AM CST
RAMAT GAN, Israel, November 19, 2013 /PRNewswire/ --
LabStyle Innovations Welcomes Dennis M. McGrath to its Board of Directors
PR Newswire - Thu Nov 14, 6:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes and related blood glucose monitoring, announced today that medical device industry expert Dennis M. McGrath has joined the company's Board of Directors.
LabStyle Innovations Reports Third Quarter 2013 Results And Provides Business Update
PR Newswire - Tue Nov 12, 7:19AM CST
LabStyle Innovations Corp. (OTCQB/OTCBB: DRIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes management and related blood glucose monitoring, reported today its financial and operational results for the three and nine months ending on September 30, 2013. The company also provided a business update and its plans for the coming months.
LabStyle Innovations Announces that the European Market Launch of the Dario(TM) Diabetes Management Platform iOS Mobile App Will Begin on December 12, 2013
PR Newswire - Mon Nov 04, 6:00AM CST
LabStyle Innovations Corp. (OTCQB: DRIO), developer of Dario(TM), a cloud-based, mobile health (mHealth) platform for diabetes and related blood glucose monitoring, announced today the official European launch date for the Dario(TM) iOS mobile application.
LabStyle Innovations Executive Chairman's Presentation at Cleveland Clinic's 2013 Medical Innovation Summit Now Available Online
Business Wire - Mon Oct 21, 9:10AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of a diabetes-related, cloud-based mobile health (mHealth) platform and the Dario(TM) blood glucose monitoring system for patients and caregivers, announces that a presentation delivered by Executive Chairman Dr. Oren Fuerst at Cleveland Clinic's 2013 Medical Innovation Summit highlighting LabStyle's latest developments is now available at www.mydario.com and at http://www.slideshare.net/oren68/dario-invest...veland-adb.
Dario Smartphone-Based Diabetes Management System Featured in Diabetes Daily Blog
Business Wire - Wed Sep 18, 3:31PM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario(TM) smartphone-based medical device and diabetes management system, announces that Dario is the subject of a comprehensive profile in Diabetes Daily, a leading online support network for people with diabetes. The article is available at:
LabStyle Innovations to Present at the Rodman & Renshaw 15TH Annual Healthcare Conference
Business Wire - Wed Sep 04, 7:00AM CDT
LabStyle Innovations Corp. (OTCQB
RIO), developer of the Dario(TM) smartphone-based medical device and diabetes management system, announces its participation in the Rodman & Renshaw 15th Annual Healthcare Conference, to be held September 9-10, 2013 at the Millennium Broadway Hotel in New York City. LabStyle Innovations Names Shoshana Friedman Vice President of Clinical and Regulatory Affairs
Business Wire - Tue Sep 03, 7:00AM CDT
LabStyle Innovations Corp. (OTCQB: DRIO), the developer of the Dario(TM) smartphone-based glucose monitor and diabetes data-management system, today announced that Shoshana (Shosh) Friedman has joined the company as Vice President Clinical and Regulatory Affairs, with responsibility for all clinical studies and worldwide regulatory affairs for Dario.
LabStyle Innovations Reports Second Quarter Results and Provides Business Update
Business Wire - Wed Aug 14, 5:38PM CDT
LabStyle Innovations Corp. (OTCQB/OTCBB
RIO), developer of the Dario(TM) smartphone-based medical device and diabetes management system, today reported its financial and operational results for the three and six months ended June 30, 2013 and provided a business update. 
